Report Detail
Global Ophthalmology Drugs Market Size, Status and Forecast 2019-2025
- RnM2749090 |
- 10 January, 2019 |
- Global |
- 98 Pages |
- QYResearch |
- Other
Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness.
Of the five key indications within the therapy area - glaucoma, AMD, DME, DR and DES - glaucoma and AMD have the most active product pipelines.
In 2018, the global Ophthalmology Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Ophthalmology Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Ophthalmology Drugs development in United States, Europe and China.
The key players covered in this study
Novartis
Regeneron
Roche
Bayer
Allergan
Shire
Mallinckrodt
Santen Pharmaceutical
Aerie
Market segment by Type, the product can be split into
Lucentis (Ranibizumab)
Eylea (Aflibercept)
Avastin (Bevacizumab)
Restasis (Cyclosporine)
Alphagan (Brimonidine Tartrate)
Lumigan (Bimatoprost)
Xalatan (Latanoprost)
Conclusion
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Ophthalmology Drugs status, future forecast, growth opportunity, key market and key players.
To present the Ophthalmology Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Ophthalmology Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Ophthalmology Drugs Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Lucentis (Ranibizumab)
- 1.4.3 Eylea (Aflibercept)
- 1.4.4 Avastin (Bevacizumab)
- 1.4.5 Restasis (Cyclosporine)
- 1.4.6 Alphagan (Brimonidine Tartrate)
- 1.4.7 Lumigan (Bimatoprost)
- 1.4.8 Xalatan (Latanoprost)
- 1.4.9 Conclusion
- 1.5 Market by Application
- 1.5.1 Global Ophthalmology Drugs Market Share by Application (2014-2025)
- 1.5.2 Hospital Pharmacies
- 1.5.3 Retail Pharmacies
- 1.5.4 Drug Stores
- 1.5.5 Online Sales
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Ophthalmology Drugs Market Size
- 2.2 Ophthalmology Drugs Growth Trends by Regions
- 2.2.1 Ophthalmology Drugs Market Size by Regions (2014-2025)
- 2.2.2 Ophthalmology Drugs Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Ophthalmology Drugs Market Size by Manufacturers
- 3.1.1 Global Ophthalmology Drugs Revenue by Manufacturers (2014-2018)
- 3.1.2 Global Ophthalmology Drugs Revenue Market Share by Manufacturers (2014-2018)
- 3.1.3 Global Ophthalmology Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Ophthalmology Drugs Key Players Head office and Area Served
- 3.3 Key Players Ophthalmology Drugs Product/Solution/Service
- 3.4 Date of Enter into Ophthalmology Drugs Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Ophthalmology Drugs Market Size by Type (2014-2019)
- 4.2 Global Ophthalmology Drugs Market Size by Application (2014-2019)
5 United States
- 5.1 United States Ophthalmology Drugs Market Size (2014-2019)
- 5.2 Ophthalmology Drugs Key Players in United States
- 5.3 United States Ophthalmology Drugs Market Size by Type
- 5.4 United States Ophthalmology Drugs Market Size by Application
6 Europe
- 6.1 Europe Ophthalmology Drugs Market Size (2014-2019)
- 6.2 Ophthalmology Drugs Key Players in Europe
- 6.3 Europe Ophthalmology Drugs Market Size by Type
- 6.4 Europe Ophthalmology Drugs Market Size by Application
7 China
- 7.1 China Ophthalmology Drugs Market Size (2014-2019)
- 7.2 Ophthalmology Drugs Key Players in China
- 7.3 China Ophthalmology Drugs Market Size by Type
- 7.4 China Ophthalmology Drugs Market Size by Application
8 Japan
- 8.1 Japan Ophthalmology Drugs Market Size (2014-2019)
- 8.2 Ophthalmology Drugs Key Players in Japan
- 8.3 Japan Ophthalmology Drugs Market Size by Type
- 8.4 Japan Ophthalmology Drugs Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Ophthalmology Drugs Market Size (2014-2019)
- 9.2 Ophthalmology Drugs Key Players in Southeast Asia
- 9.3 Southeast Asia Ophthalmology Drugs Market Size by Type
- 9.4 Southeast Asia Ophthalmology Drugs Market Size by Application
10 India
- 10.1 India Ophthalmology Drugs Market Size (2014-2019)
- 10.2 Ophthalmology Drugs Key Players in India
- 10.3 India Ophthalmology Drugs Market Size by Type
- 10.4 India Ophthalmology Drugs Market Size by Application
11 Central & South America
- 11.1 Central & South America Ophthalmology Drugs Market Size (2014-2019)
- 11.2 Ophthalmology Drugs Key Players in Central & South America
- 11.3 Central & South America Ophthalmology Drugs Market Size by Type
- 11.4 Central & South America Ophthalmology Drugs Market Size by Application
12 International Players Profiles
- 12.1 Novartis
- 12.1.1 Novartis Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Ophthalmology Drugs Introduction
- 12.1.4 Novartis Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.1.5 Novartis Recent Development
- 12.2 Regeneron
- 12.2.1 Regeneron Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Ophthalmology Drugs Introduction
- 12.2.4 Regeneron Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.2.5 Regeneron Recent Development
- 12.3 Roche
- 12.3.1 Roche Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Ophthalmology Drugs Introduction
- 12.3.4 Roche Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.3.5 Roche Recent Development
- 12.4 Bayer
- 12.4.1 Bayer Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Ophthalmology Drugs Introduction
- 12.4.4 Bayer Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.4.5 Bayer Recent Development
- 12.5 Allergan
- 12.5.1 Allergan Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Ophthalmology Drugs Introduction
- 12.5.4 Allergan Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.5.5 Allergan Recent Development
- 12.6 Shire
- 12.6.1 Shire Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Ophthalmology Drugs Introduction
- 12.6.4 Shire Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.6.5 Shire Recent Development
- 12.7 Mallinckrodt
- 12.7.1 Mallinckrodt Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Ophthalmology Drugs Introduction
- 12.7.4 Mallinckrodt Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.7.5 Mallinckrodt Recent Development
- 12.8 Santen Pharmaceutical
- 12.8.1 Santen Pharmaceutical Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Ophthalmology Drugs Introduction
- 12.8.4 Santen Pharmaceutical Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.8.5 Santen Pharmaceutical Recent Development
- 12.9 Aerie
- 12.9.1 Aerie Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Ophthalmology Drugs Introduction
- 12.9.4 Aerie Revenue in Ophthalmology Drugs Business (2014-2019)
- 12.9.5 Aerie Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Ophthalmology Drugs . Industry analysis & Market Report on Ophthalmology Drugs is a syndicated market report, published as Global Ophthalmology Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Ophthalmology Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
